MedTrace Logo

Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT03746652 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-11-23

No results posted yet for this study

Summary

This study will assess the efficacy of daratumumab in combination with ixazomib and dexamethasone as second line treatment for relapsed Multiple Myeloma patients.

Conditions

Interventions

DRUG

Daratumumab, Ixazomib, Dexamethasone

Daratumumab 16 mg/kg, Ixazomib 4 mg, Dexamethasone 40 mg

Sponsors & Collaborators

  • Janssen Pharmaceutica NV

    collaborator UNKNOWN

  • Takeda

    collaborator INDUSTRY

  • Hellenic Society of Hematology

    lead OTHER

Principal Investigators

  • Evangelos Terpos, Prof. · Department of Clinical therapeutics, National and Kapodistrian University of Athens, School of medicine, Athens, Greece

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-31
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03746652 on ClinicalTrials.gov